Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials

Shangli Cai,1,2 Huafei Lu,2 Zhihua Bai,2 Renrong Wu,1 Jingping Zhao1 1Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Hunan, 2Janssen Research and Develop...

Full description

Bibliographic Details
Main Authors:	Cai SL, Lu HF, Bai ZH, Wu RR, Zhao JP
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-07-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/paliperidone-extended-release-tablets-in-chinese-patients-with-schizop-peer-reviewed-article-NDT

Similar Items

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
by: Yang FD, et al.
Published: (2017-04-01)

Formulation and In Vitro Evaluation of Extended Release Tablets of Paliperidone Using Natural Gums
by: bharghav bhushan rao
Published: (2018-03-01)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
by: Taro Kishi, et al.
Published: (2022-12-01)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-02-01)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
by: Jariyavilas A, et al.
Published: (2017-01-01)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
by: Nakagawa R, et al.
Published: (2015-06-01)

Tablets of paliperidone using compression-coated technology for controlled ascending release
by: Yingying Tang, et al.
Published: (2018-03-01)

Treatment of bipolar mania with paliperidone extended-release
by: Paterakis Periklis, et al.
Published: (2010-04-01)

The role of paliperidone extended release for the treatment of bipolar disorder
by: Marino J, et al.
Published: (2012-04-01)

Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study
by: Gang Wang, et al.
Published: (2019-09-01)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
by: Zhao JP, et al.
Published: (2017-08-01)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
by: Li N, et al.
Published: (2018-03-01)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
by: Gang Wang, et al.
Published: (2020-04-01)

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
by: Kongsakon R, et al.
Published: (2017-10-01)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
by: Si TM, et al.
Published: (2015-01-01)

Paliperidone extended-release: does it have a place in antipsychotic therapy?
by: Carlos Sch&ouml;nfeldt-Lecuona, et al.
Published: (2011-03-01)

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
by: Patrick, D, et al.
Published: (2010)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
by: Charnsil C, et al.
Published: (2013-08-01)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
by: González-Rodríguez A, et al.
Published: (2015-05-01)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
by: Papanicolaou Sotiria, et al.
Published: (2008-08-01)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
by: Papanicolaou Sotiria, et al.
Published: (2009-06-01)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
by: Jara M, et al.
Published: (2014-12-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study
by: Gahan Pandina, et al.
Published: (2020-06-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China
by: Rui Luo, et al.
Published: (2023-08-01)

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report
by: Hassan Mirza, et al.
Published: (2018-09-01)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
by: Kim S, et al.
Published: (2012-07-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
by: Azin Abdollahi, et al.
Published: (2023-07-01)

Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis
by: Yang X, et al.
Published: (2015-03-01)

Patient social function and quality of life in schizophrenia: focus on paliperidone palmitate
by: E. V. Grigorieva
Published: (2018-07-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
by: Zhang F, et al.
Published: (2015-03-01)

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
by: Michael Birnbaum, et al.
Published: (2008-12-01)

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
by: Amber N. Edinoff, et al.
Published: (2021-09-01)

Metoprolol succinate extended release/hydrochlorothiazide combination tablets
by: James W Hainer, et al.
Published: (2007-07-01)

Factors Affecting the Formulation of Carbamazepine Extended Release Tablet
by: Samer H. Aziz, et al.
Published: (2017-03-01)